Aims and objectives
Invasive lobular carcinoma (ILC) is the second most common histologic type of breast cancer occuring in approximately 10-15% of all breast cancer patients 1 .
ILC is often mammographically occult and multifocal,
consequently breast MRI in addition to conventional imaging modalities may be considered 2,3 . Contrast-enhanced spectral mammography (CESM) has the ability to detect breast cancers by visualizing enhancing neovascularity in a fashion similar to MRI 4-6 .
If diagnostic performance of...
Methods and materials
In this HPAA compliant two-center retrospective study 22 patients with ILC,
who underwent CESM and breast MRI before surgery between 2010 - 2017 were included.
Exclusion criteria were patients treated with neoadjuvant systemic therapy or patients who underwent CESM or MRI only. Data were retrospectively collected for age,
histopathology and tumor diameter measurements on CESM and MRI exams.Tumor size measurements on CESM and MRI were compared to histopathological tumor size,...
Mean tumor size measurements were 23.05 mm on CESM,
23.50 on breast MRI and 18.05 mm according to histopathology.
Mean difference in tumor size measurements between CESM and histopathology was 5.0 mm (PCC 0.853,
p<0.001) compared to 5.5 mm between breast MRI and histopathology (PCC 0.816,
Breast MRI detected 7 additional lesions not seen on CESM,
of which two ipsilateral lesions were malignant (one lesion of 8 mm with invasive ductal carcinoma,
resulting in double lumpectomy of the...
Evaluation of primary tumour size in ILC seems depicted equally well by CESM and MRI.
Regarding the assessment of disease extent,
breast MRI results in more false-positive findings,
whereas CESM was less sensitive.
PhD, Department of Radiology and Nuclear Medicine Maastricht University Medical Center + P.O.
Box 5800 6202 AZ Maastricht,
the Netherlands. Phone: +31 43 387 6910 E-mail: Thiemo.email@example.com
Trends in incidence rates of invasive lobular and ductal breast carcinoma.
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis,
treatment and follow-up.
2015;26 Suppl 5:v8-30. 3.
Invasive Breast Cancer Version 1.2016,
NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw.